Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS (Tables)

v3.22.1
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS (Tables)
3 Months Ended
Mar. 31, 2022
REVENUES FROM CONTRACTS AND SIGNIFICANT CUSTOMERS  
Schedule of disaggregation of net revenues

The Company’s net product revenues are summarized as follows:

    

Three-Month Periods Ended March 31, 

($ in thousands)

    

2022

    

2021

Qbrexa®

$

7,376

$

Accutane®

 

4,907

 

196

Amzeeq®

3,466

Targadox®

2,634

7,199

Ximino®

967

2,100

Zilxi®

741

Exelderm®

 

704

 

1,217

Other branded revenue

 

1

 

7

Total product revenues

$

20,796

$

10,719